Open AccessFour-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents
Author(s) -
Alessia Biolchi,
Sara Tomei,
Laura Santini,
Rita La Gaetana,
Elena Mori,
Patricia Novy,
Rino Rappuoli,
Rafik Bekkat-Berkani,
Marzia M. Giuliani,
Mariagrazia Pizza
Publication year - 2020
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002957
Subject(s) - outbreak , neisseria meningitidis , titer , meningococcal vaccine , medicine , strain (injury) , meningococcal disease , meningitis , virology , microbiology and biotechnology , antibody , immunization , biology , bacteria , immunology , virus , pediatrics , genetics
Neisseria meningitidis serogroup B (MenB) causes most meningitis outbreaks worldwide. We evaluated the ability of the 4-component MenB vaccine (4CMenB) to induce bactericidal activity against outbreak strains in adolescents.